S-1 Impact 6/10 Ipo / Direct Listing

$MXRX · MED-X, INC.

November 17, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Med-X, Inc. filed Amendment No. 4 to its Form S-1 to register the resale of up to 16,248,842 post-split common shares by existing stockholders in connection with a direct listing on the Nasdaq Global Market under symbol MXRX. The company raised approximately $38,081,204 in net proceeds from inception (Feb 14, 2014) through Oct 14, 2026 at an average post-split price of $2.89 per share. A 1-for-2 reverse stock split was approved June 1, 2026, effective after the registration statement is declared effective but before listing.

  • Resale registration covers up to 16,248,842 post-split shares; company receives no proceeds from stockholder sales.
  • Chairman/CEO holds ~54.3% of total voting power via Series A super-voting preferred stock plus common and options.
  • 1-for-2 reverse split approved June 1, 2026; authorized shares remain 300,000,000.
  • Maxim Group LLC engaged as financial advisor for the direct listing.
  • No public market currently exists; listing on Nasdaq is a condition to completing the offering.

Price data unavailable.

A small natural-products company is pursuing a Nasdaq direct listing with no underwritten offering, making listing approval the pivotal binary event.

Direct listings without a firm-commitment underwriter are a novel listing method, and the filing warns trading may be more volatile than a traditional IPO.

Nasdaq approval is not assured; if denied, the direct listing will be terminated. Concentrated voting control (~54.3%) rests with the Chairman/CEO, limiting minority shareholder influence.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →